Physician profile
Amanda Lewton
NPI 1922329382
$2,066.61
in general payments reported to CMS, 2019-2025
28 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $280 · 2021: $281 · 2022: $155 · 2023: $186 · 2024: $188 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.47 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $348.85 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $267.93 | 2019-2024 | |
| Abbvie INC. | $210.79 | 2021-2024 | |
| Allergan, INC. | $201.43 | 2019-2020 | |
| Amgen INC. | $127.98 | 2019-2024 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.89 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $84.76 | 2019-2025 | Kisunla |
| Novartis Pharmaceuticals Corporation | $84.27 | 2020-2024 | |
| Glaxosmithkline, LLC. | $65.89 | 2019-2025 | Trelegy Ellipta, Rotarix, Bexsero |
| Otsuka America Pharmaceutical, INC. | $63.73 | 2019-2024 | Rexulti |
| Novo Nordisk INC | $63.37 | 2020-2024 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $53.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.03 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $37.92 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $33.72 | 2021-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $33.21 | 2020-2021 | |
| Abbott Laboratories | $31.29 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $28.60 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $27.92 | 2021 | |
| Astellas Pharma US INC | $23.58 | 2020 | |
| Vanda Pharmaceuticals INC. | $20.18 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.56 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.16 | 2024 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $16.84 | 2021 | |
| Exact Sciences Corporation | $15.22 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $14.60 | 2022 | |
| Amarin Pharma, INC. | $13.11 | 2021 | |
| Eisai INC. | $12.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lewton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.